Sun Pharma Organon acquisition: $11.75B deal boosts global presence, biosimilars entry, and revenues to $12.4B. Full analysis of risks, strategy, and impact.
FDA approves Icotyde, J&J’s once-daily psoriasis pill, offering an oral alternative to costly injectable drugs like Tremfya and Skyrizi.
